REAL

Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting

Pongor, Lőrinc and Munkácsy, Gyöngyi and Vereczkey, Ildikó and Pete, Imre and Győrffy, Balázs (2020) Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting. SCIENTIFIC REPORTS, 10 (1). ISSN 2045-2322

[img]
Preview
Text
s41598-020-71382-3.pdf

Download (3MB) | Preview

Abstract

Tumor heterogeneity is a consequence of clonal evolution, resulting in a fractal-like architecture with spatially separated main clones, sub-clones and single-cells. As sequencing an entire tumor is not feasible, we ask the question whether there is an optimal clinical sampling strategy that can handle heterogeneity and hypermutations? Here, we tested the effect of sample size, pooling strategy as well as sequencing depth using whole-exome sequencing of ovarian tumor specimens paired with normal blood samples. Our study has an emphasis on clinical application—hence we compared single biopsy, combined local biopsies and combined multi-regional biopsies. Our results show that sequencing from spatially neighboring regions show similar genetic compositions, with few private mutations. Pooling samples from multiple distinct regions of the primary tumor did not increase the overall number of identified mutations but may increase the robustness of detecting clonal mutations. Hypermutating tumors are a special case, since increasing sample size can easily dilute sub-clonal private mutations below detection thresholds. In summary, we compared the effects of sampling strategies (single biopsy, multiple local samples, pooled global sample) on mutation detection by next generation sequencing. In view of the limitations of present tools and technologies, only one sequencing run per sample combined with high coverage (100–300 ×) sequencing is affordable and practical, regardless of the number of samples taken from the same patient. © 2020, The Author(s).

Item Type: Article
Additional Information: Department of Bioinformatics, Semmelweis University, Budapest, Hungary Momentum Cancer Biomarker Research Group, Institute of Enzymology, Research Center for Natural Sciences, Budapest, Hungary National Institute of Oncology, Budapest, Hungary 2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary Export Date: 22 September 2020 Correspondence Address: Győrffy, B.; Department of Bioinformatics, Semmelweis UniversityHungary; email: gyorffy.balazs@med.semmelweis-univ.hu Funding details: Semmelweis Egyetem Funding text 1: The research was financed by the 2018-2.1.17-TET-KR-00001 and KH-129581 grants and by the Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary, within the framework of the Bionic thematic programme of the Semmelweis University. The authors acknowledge the support of ELIXIR Hungary (www.elixir-hungary.org).
Subjects: R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában
SWORD Depositor: MTMT SWORD
Depositing User: MTMT SWORD
Date Deposited: 22 Sep 2020 14:01
Last Modified: 22 Sep 2020 14:01
URI: http://real.mtak.hu/id/eprint/114051

Actions (login required)

Edit Item Edit Item